In the first days of each year, 24/7 Wall St. uses the average implied upside of each Dow Jones Industrial Average component to generate an upside price target. It has been off…
November 10, 2016: Markets opened higher Thursday but the tech heavy Nasdaq Composite soon fell into the red and may not make it out by the end of the trading session. The…
Drug prices have been under pressure due to the campaign rhetoric, and short interest has increased in most of these selected pharmaceutical stocks.
November 9, 2016: Markets opened lower again Wednesday following the unexpected results of Tuesday’s election. Overnight DJIA futures dropped some 800 points at one point, but equities gained strength throughout the day…
24/7 Wall St. has identified several immediate winners from a Donald Trump presidency. These are all surging higher.
FactSet set its computers to work counting the number of times company executives mentioned the word "election" during third-quarter conference calls.
November 3, 2016: Markets opened higher Thursday but drifted lower around midday. Friday morning brings the non-farm payroll report which is expected to show that 178,000 jobs were added in October and…
The top analyst upgrades, downgrades and initiations seen on Wednesday morning include Brookdale Senior Living, Frontier Communications, Nike, Norfolk Southern, Pfizer, Nucor and Xylem.
November 1, 2016: Markets opened higher again Tuesday but drifted lower beginning in the mid-morning, and appear on track for a lower close. Consumer discretionary and real-estate sectors were among the day’s…
As Pfizer is a major player in the pharmaceutical industry, this earnings report is important in setting a direction that other companies can rally behind.
Chris Lange Pfizer is scheduled to release its third-quarter financial results before the markets open on Tuesday.
Chris Lange 24/7 Wall St. has put together a preview of Pfizer, Starbucks and some of the major companies reporting their quarterly results this week.
The October 14 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short interest was mixed.
Savvy investors know that often the best time to buy a stock, especially a solid company with a mature franchise, is when an event that falls outside the norm affects the stock's…
Alkermes' positive Phase 3 results for its novel antidepressant is serving as a rising tide — a storm surge even — for many biotech companies in the depression space.
